Retraction—“Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” (The Lancet, (S0140673620311806), (10.1016/S0140-6736(20)31180-6));RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

The Lancet

Volumn 395, Issue 10240, 2020, Pages 1820-

  Mehra, Mandeep R ^a   Desai, Sapan S ^b   Ruschitzka, Frank ^c   Patel, Amit N ^d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Surgisphere Corporation   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Department of Electrical and Computer Engineering   (United States)

^e HOSPITAL CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETRACTION NOTICE;

EID: 85084991704     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)31324-6     Document Type: Erratum

References (28)

1. Principi, N, Esposito, S, Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis, 2020 published online April 17. https://doi.org/10.1016/S1473-3099(20)30296-6.
2. Perricone, C, Triggianese, P, Bartoloni, E, et al. The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. J Autoimmun, 2020 published online April 17. DOI:10.1016/j.jaut.2020.102468.
3. Liu, J, Cao, R, Xu, M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov, 6, 2020, 16.
4. Devaux, CA, Rolain, JM, Colson, P, Raoult, D, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents, 2020 published online March 12. DOI:10.1016/j.ijantimicag.2020.105938.
5. Tang, W, Cao, Z, Han, M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv, 2020 published online May 7. DOI: 10.1101/2020.04.10.20060558 (preprint).
6. Chen, J, Liu, D, Liu, L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ (Med Sci) 49 (2020), 215–219.
7. Gautret, P, Lagier, JC, Parola, P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020 published online March 20. DOI:10.1016/j.ijantimicag.2020.105949.
8. Ray, WA, Murray, KT, Hall, K, Arbogast, PG, Stein, CM, Azithromycin and the risk of cardiovascular death. N Engl J Med 366 (2012), 1881–1890.
9. Giudicessi, JR, Noseworthy, PA, Friedman, PA, Ackerman, MJ, Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc, 2020 published online April 7. DOI:10.1016/j.mayocp.2020.03.024.
10. Peschken, CA, Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 pandemic. J Rheumatol, 2020 published online April 8. DOI:10.3899/jrheum.200395.
11. WHO. Clinical management of severe acute respiratory infection (SARI) when novel COVID-19 disease is suspected: interim guidance. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf, March 13, 2020. (Accessed 24 April 2020)
12. US Food and Drug Administration. Emergency use authorization: coronavirus disease 2019 (COVID-19) EUA information. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covidtherapeutics. (Accessed 15 May 2020)
13. Gao, J, Tian, Z, Yang, X, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14 (2020), 72–73.
14. Magagnoli, J, Narendran, S, Pereira, F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. medRxiv, 2020 published online April 23. DOI: 10.1101/2020.04.16.20065920 (preprint).
15. Mahevas, M, Tran, V-T, Roumier, M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection with oxygen requiremenr: results of a study using routinely collected data to emulate a target trial. medRxiv, 2020 published online April 14. DOI: 10.1101/2020.04.10.20060699 (preprint).
16. Traebert, M, Dumotier, B, Meister, L, Hoffmann, P, Dominguez-Estevez, M, Suter, W, Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484 (2004), 41–48.
17. Shi, S, Qin, M, Shen, B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol, 2020 published online March 25. DOI:10.1001/jamacardio.2020.0950.
18. Guo, T, Fan, Y, Chen, M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020 published online March 27. DOI:10.1001/jamacardio.2020.1017.
19. Bonow, RO, Fonarow, GC, O'Gara, PT, Yancy, CW, Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol, 2020 published online March 27. DOI:10.1001/jamacardio.2020.1105.
20. Mehra, MR, Desai, SS, Kuy, S, Henry, TD, Patel, AN, Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med, 2020 published online May 1. DOI:10.1056/NEJMoa2007621.
21. Varga, Z, Flammer, AJ, Steiger, P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395 (2020), 1417–1418.
22. Siddiqi, HK, Mehra, MR, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 39 (2020), 405–407.
23. Nakornchai, S, Konthiang, P, Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop 100 (2006), 185–191.
24. Lee, N, Wong, CK, Chan, MCW, et al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antiviral Res 144 (2017), 48–56.
25. Borba, MGS, Val, FFA, Sampaio, VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open, 3, 2020, e208857.
26. Mercuro, NJ, Yen, CF, Shim, DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020 published online May 1. DOI:10.1001/jamacardio.2020.1834.
27. Lavie, CJ, Arena, R, Alpert, MA, Milani, RV, Ventura, HO, Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol 15 (2018), 45–56.
28. Sanchis-Gomar, F, Lavie, CJ, Mehra, MR, Henry, BM, Lippi, G, Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc, 2020 published online May 19. DOI:10.1016/j.mayocp.2020.05.006.